Ticagrelor
Ticagrelor is a pharmaceutical drug with 226 clinical trials. Currently 9 active trials ongoing. Historical success rate of 93.9%.
Success Metrics
Based on 155 completed trials
Phase Distribution
Phase Distribution
20
Early Stage
28
Mid Stage
148
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
89.6%
155 of 173 finished
10.4%
18 ended early
9
trials recruiting
226
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
The Safety and Efficacy Of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention
Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months
IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome
Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.
TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement
Clinical Trials (226)
The Safety and Efficacy Of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention
Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months
IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome
Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.
TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement
DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury
The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin
A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects
TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome.
Multicentric Study on Clopidogrel Resistance in DAPT for CAS (MULTI-RESCLOSA)
The Effect of IV Cangrelor and Oral Ticagrelor Study
A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants
Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction
Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects
A REAl-life Study on Short-term DAPT in Patients With Ischemic Stroke or TIA
TISSARA Trial: Ticagrelor Intervention to Reduce Stent Thrombosis and Acute MI Risk
Chewed Versus Integral Pill of Ticagrelor
Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction and the Effect on Intramyocardial Haemorrhage
Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention
CES1 Crossover Trial of Clopidogrel and Ticagrelor
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 226